nature portfolio

Corresponding author(s):	Levin, NCOMMS-23-27594
Last updated by author(s):	Dec 1, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

\sim	0.00	100	
Sta	11	۲†۱	CS

/-		
n/a	Cor	firmed
	X	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	x	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X		A description of all covariates tested
	x	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	x	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
x		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Xenopus laevis rRNA sequences were mapped to NCBI nucleotide database

Data analysis

For statistics, data were analyzed using Graph Prism9 (Version 9.1.0). For microscopy, images were taken with Nikon SMZ1500 microscope with a Retiga 2000R camera and Q-capture imaging software. Images were then analyzed using ImageJ. For RNA seq, Bowtie2 was used to align reads, samtools was used to extract reads that were not mapped, STAR aligner with the two-pass option was used to align adapter-trimmed reads to the genome. All models were built using the MATLAB software (9.12.0.1884302, R2022a).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data generated or analyzed during this study are available in the source data file

Research involving human participants, their data, or biological material

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism.

Reporting on sex and gender

Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design; whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data, where this information has been collected, and if consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this

information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.

Reporting on race, ethnicity, or other socially relevant groupings

Please specify the socially constructed or socially relevant categorization variable(s) used in your manuscript and explain why they were used. Please note that such variables should not be used as proxies for other socially constructed/relevant variables (for example, race or ethnicity should not be used as a proxy for socioeconomic status).

Provide clear definitions of the relevant terms used, how they were provided (by the participants/respondents, the researchers, or third parties), and the method(s) used to classify people into the different categories (e.g. self-report, census or administrative data social media data etc.)

Please provide details about how you controlled for confounding variables in your analyses.

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ecological, evolutionary & environmental sciences

Ethics oversight

Life sciences

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for y	your research. It	If you are not sure, read	d the appropriate sections b	efore making your selection.

☐ Behavioural & social sciences For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample size calculation was performed because this study is based on varying cohort size
Data exclusions	No data was excluded
Replication	All experiments were repeated independently at least three times across multiple weeks with the number of embryos indicated in each group as indicated in figure legends.
Randomization	Xenopus laevis embryos were randomly assigned to each experimental group before treatment.
Blinding	Blind scoring at the data collection stage was done at least once in each triplicate trial.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

	E
٤	د
Ī	
5	\$
۶	
ŗ	Ş
	ì

Materials & experime	ental systems Methods	
n/a Involved in the study	n/a Involved in the study	
X Antibodies	ChIP-seq	
x Eukaryotic cell lines	Flow cytometry	
Palaeontology and a	archaeology MRI-based neuroimaging	
Animals and other of	organisms	
Clinical data		
Dual use research o	f concern	
✗ ☐ Plants		
	r research organisms udies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in	
Laboratory animals	Xenopus laevis wildtype and albinos from 2011-2022 were used for embryo collection. Embryos were collected at the two cell stage and raised till NF stage 45.	
Wild animals	No wild animals were used in this study	
Reporting on sex	Sex was not considered in this study	
Field-collected samples	No field collected samples were used in this study	
Ethics oversight	Ethical approval was received from Institutional Animal Care and Use Committee through Tufts University (protocol number M2023-18).	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.